Urinary tract cancers are increasingly being approached through a combination of surgical intervention, systemic therapies, immunotherapy and molecularly guided treatment. Bladder cancer represents a particularly important part of this landscape, alongside cancers affecting the kidneys, ureters and other urinary structures.
-
According to the International Agency for Research on Cancer's GLOBOCAN 2022 estimates, bladder cancer accounted for approximately 614,298 new cases and 220,596 deaths worldwide.
-
These figures illustrate why improvements in treatment access, recurrence management and long-term disease control remain important healthcare priorities.
A New Treatment Combination Reaches High-Risk Bladder Cancer
One of the most notable developments in 2026 came on May 28, when the US Food and Drug Administration (FDA) approved durvalumab in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer.
The approval followed the POTOMAC clinical trial, which enrolled 1,018 patients. This development is significant because it introduces an immunotherapy-based combination into an earlier stage of bladder cancer management, rather than reserving systemic immune treatment primarily for advanced disease.
When Existing BCG Treatment Is No Longer Enough
Treatment resistance and recurrence remain difficult clinical issues for patients with high-risk non-muscle-invasive bladder cancer. On October 14, 2026, the FDA expanded the indication for nogapendekin alfa inbakicept (Anktiva) in combination with BCG to include adults with BCG-unresponsive disease presenting with high-grade papillary-only tumours.
The earlier indication covered carcinoma in situ, with or without papillary tumours. This expansion provides another treatment option for a patient group in which maintaining disease control without immediate bladder removal can be an important consideration.
The Operating Room Is Becoming Part of a Larger Treatment Strategy
-
For muscle-invasive bladder cancer, surgery is no longer considered independently of the therapies that precede or follow it.
-
The FDA's July 10, 2026 approval of pembrolizumab, or pembrolizumab combined with berahyaluronidase alfa, alongside enfortumab vedotin, marked an important expansion of perioperative treatment.
-
The regimen can be used before radical cystectomy and continued through postoperative treatment in eligible adults with muscle-invasive disease who are candidates for surgery.
-
The approval extended the approach beyond patients who were ineligible for cisplatin-based chemotherapy. The underlying KEYNOTE-B15/EV-304 study enrolled 808 patients.
-
This development highlights a wider change in clinical practice: oncologists are evaluating how treatment combinations can address cancer before surgery while also reducing the risk of disease returning afterwards.
Delivering Treatment Directly Where the Tumour Develops
Intravesical therapy remains an important part of bladder cancer management because medication can be delivered directly into the bladder through a catheter. This approach is particularly relevant for non-muscle-invasive disease, where preserving the bladder while controlling tumour recurrence is a major clinical objective.
The FDA's September 2025 approval of Inlexzo, a gemcitabine intravesical system, introduced another delivery approach for patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. The system is administered into the bladder and releases gemcitabine over time. Its clinical evaluation in the SunRISe-1 study involved 83 patients in the relevant cohort. This illustrates how drug-delivery technology is becoming an important part of urological cancer treatment, alongside the development of new pharmaceutical molecules.
For a more thorough report, please contact us using our most recent report: https://www.24lifesciences.com/urinary-tract-cancer-treatment-market-14545
Molecular Testing Is Changing How Advanced Disease Is Classified
-
Not every urinary tract tumour responds to the same treatment. Molecular differences can influence disease progression and determine whether a patient may benefit from a particular targeted medicine.
-
FGFR3 alterations are one example in urothelial carcinoma. The European Association of Urology's 2025 muscle-invasive and metastatic bladder cancer recommendations incorporated the use of susceptible FGFR3 alterations to identify patients with unresectable or metastatic disease who may be candidates for erdafitinib.
-
HER2 overexpression is another relevant biomarker, with updated European guidance addressing trastuzumab deruxtecan in selected metastatic cases.
-
These developments strengthen the connection between pathology laboratories, molecular diagnostics and oncology departments. Treatment selection increasingly depends on understanding the biological characteristics of an individual's tumour, rather than relying exclusively on its anatomical location.
Preserving the Bladder without Compromising Clinical Control
Radical cystectomy can be an essential treatment for selected patients with muscle-invasive bladder cancer, but removal of the bladder brings substantial changes to everyday life. Urinary diversion, recovery, body-image concerns and long-term monitoring all become part of the patient's treatment experience.
Bladder-preserving trimodality treatment, generally combining maximal transurethral tumour resection, radiotherapy and chemotherapy, offers an alternative for appropriately selected patients. The European Association of Urology's 2026 guidelines place greater emphasis on patient-centred clinical pathways, multidisciplinary decisions and evidence-based treatment planning. Importantly, bladder preservation is not appropriate for everyone, and close follow-up remains essential.
The Next Clinical Priority: Connecting Innovation with Everyday Care
The changing treatment landscape also places greater importance on access to specialist urological oncology services, reliable pathology, molecular testing and coordinated follow-up. Patients with recurrent disease may require repeated cystoscopy, imaging, urine cytology and treatment reassessment. These requirements make continuity of care just as important as the initial drug choice.
-
The National Cancer Institute's regularly updated bladder cancer treatment information lists several therapeutic options, including pembrolizumab, enfortumab vedotin, erdafitinib, durvalumab and newer intravesical treatments.
-
Their availability and approved indications differ by country, making local regulatory guidance and individual clinical assessment essential.
Ultimately, the most meaningful development in urinary tract cancer treatment is not simply the arrival of another medicine. It is the growing ability to match treatment intensity, delivery method and therapeutic combinations to the patient's disease characteristics. As clinical evidence continues to evolve, the connection between precision diagnostics, multidisciplinary oncology and long-term patient care will remain central to improving treatment outcomes.